Advertisement

Sexualhormone

  • Thomas StrowitzkiEmail author
Chapter
  • 1.1k Downloads

Auf einen Blick

VerordnungsprofilDie wichtigsten Gruppen der Sexualhormone sind Östrogenpräparate und Kontrazeptiva. Danach folgen mit weitem Abstand Gestagene. Die Verordnungen aller Östrogenpräparate zur Hormontherapie in der Postmenopause (systemische und topische Präparate) sind seit 2009 erneut um 21 % zurückgegangen. Von 2017 auf 2018 trat nur noch ein minimaler weiterer Gesamtrückgang insbesondere bei Kombinationspräparaten ein bei einer leichten Zunahme von Östrogenmonopräparaten. Damit wird auch 2018 der Effekt der Leitlinienempfehlungen zur postmenopausalen Hormontherapie mit weiterhin stabilen Verordnungszahlen sichtbar. Nach langjähriger Konstanz zeigten auch die hormonalen Kontrazeptiva seit 2008 eine kontinuierliche Verordnungsabnahme seit 2009 um 30 % bis 2018. Allein von 2017 bis 2018 gingen die Verordnungszahlen um 6 % zurück. Die Gestagenverordnungen haben von 2017 bis 2018 deutlich zugenommen. Reine Gestagenpräparate zur Kontrazeption haben mit mehr als 20 % einen...

Literatur

  1. American College of Obstetricians and Gynecologists (2013) Committee opinion no. 556: Postmenopausal estrogen therapy: route of administration and risk of venous thromboembolism. Obstet Gynecol 121:887–890CrossRefGoogle Scholar
  2. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, Eder R, Tennstedt S, Ulloor J, Zhang A, Choong K, Lakshman KM, Mazer NA, Miciek R, Krasnoff J, Elmi A, Knapp PE, Brooks B, Appleman E, Aggarwal S, Bhasin G, Hede-Brierley L, Bhatia A, Collins L, LeBrasseur N, Fiore LD, Bhasin S (2010) Adverse events associated with testosterone administration. N Engl J Med 363:109–122CrossRefGoogle Scholar
  3. de Bastos M, Stegeman BH, Rosendaal FR, Van Hylckama Vlieg A, Helmerhorst FM, Stijnen T, Dekkers OM (2014) Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev.  https://doi.org/10.1002/14651858.CD010813.pub2CrossRefPubMedGoogle Scholar
  4. Beral V, Doll R, Hermon C, Peto R, Reeves G (2008) Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controls. Lancet 371:303–314CrossRefGoogle Scholar
  5. Bundesminister für Gesundheit (2015): Verordnung zur Änderung der Arzneimittelverschreibungsverordnung und der Apothekenbetriebsordnung vom 6. März 2015. Bundesgesetzblatt 2015, Teil I, Nr. 10, Seite 278, ausgegeben zu Bonn am 13. März 2015Google Scholar
  6. Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Lévesque H, Trillot N, Barrellier MT, Wahl D, Emmerich J, Scarabin PY, Estrogen and Thromboembolism Risk (ESTHER) Study Group (2007) Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 115:840–845CrossRefGoogle Scholar
  7. Cheng L, Gulmezoglu AM, Oel CJ, Piaggio G, Ezcurra E, Look PF (2004) Interventions for emergency contraception. Cochrane Database Syst Rev 2004; (3): CD001324Google Scholar
  8. Chester RC, Kling JM, Manson JE (2018) What the Women’s Health Initiative has taught us about menopausal hormone therapy. Clin Cardiol 41:247–252CrossRefGoogle Scholar
  9. Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, Manson JE, Stefanick ML, Ockene J, Sarto GE, Johnson KC, Wactawski-Wende J, Ravdin PM, Schenken R, Hendrix SL, Rajkovic A, Rohan TE, Yasmeen S, Prentice RL, WHI Investigators (2010) Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 304:1684–1692CrossRefGoogle Scholar
  10. Cogliano V, Grosse Y, Baan R, Straif K, Secretan B, El Ghissassi F, WHO International Agency for Research on Cancer (2005) Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncol 6:552–553CrossRefGoogle Scholar
  11. Creinin MD, Schlaff W, Archer DF, Wan L, Frezieres R, Thomas M, Rosenberg M, Higgins J (2006) Progesterone receptor modulator for emergency contraception: a randomized controlled trial. Obstet Gynecol 108:1089–1097CrossRefGoogle Scholar
  12. Deutsche Gesellschaf t für Gynäkologie und Geburtshilfe (2018) Peri- und Postmenopause – Diagnostik und Interventionen. http://www.awmf.org/leitlinien/detail/ll/015-062.htmlGoogle Scholar
  13. Dinger J, Assmann A, Möhner S, Minh TD (2010) Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study. J Fam Plann Reprod Health Care 36:123–129CrossRefGoogle Scholar
  14. Food and Drug Administration (2018) FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use. https://www.fda.gov/Drugs/DrugSafety/ucm436259.htmGoogle Scholar
  15. Ford O, Lethaby A, Roberts H, Mol BW (2012) Progesterone for premenstrual syndrome. Cochrane Database Syst Rev 2012 Mar 14; 3: CD003415Google Scholar
  16. Gronich N, Lavi I, Rennert G (2011) Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study. CMAJ 183:E1319–1325CrossRefGoogle Scholar
  17. Heiss G, Wallace R, Anderson GL, Aragaki A, Beresford SA, Brzyski R, Chlebowski RT, Gass M, LaCroix A, Manson JE, Prentice RL, Rossouw J, Stefanick ML, WHI Investigators (2008) Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 299:1036–1045CrossRefGoogle Scholar
  18. Hilbert-Walter A, Büttner R, Sieber C, Bollheimer C (2013) Testosteron im Alter: ein Update. Dtsch Med Wochenschr 137:2117–2122Google Scholar
  19. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C (1995) Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 346:1589–1593CrossRefGoogle Scholar
  20. Keaney JF, Solomon CG (2016) Postmenopausal hormone therapy and atherosclerosis – Time is of the essence. N Engl J Med 374:1279–1280CrossRefGoogle Scholar
  21. Kemmeren JM, Algra A, Grobbee DE (2001) Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. Brit Med J 323:1–9CrossRefGoogle Scholar
  22. LaCroix AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC, Martin L, Margolis KL, Stefanick ML, Brzyski R, Curb JD, Howard BV, Lewis CE, Wactawski-Wende J, WHI Investigators (2011) Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 305:1305–1314CrossRefGoogle Scholar
  23. Lidegaard O, Nielsen LH, Skovlund CW, Løkkegaard E (2012) Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001–10. BMJ 344:e2990.  https://doi.org/10.1136/bmj.e2990CrossRefPubMedPubMedCentralGoogle Scholar
  24. Lidegaard Ø, Nielsen LH, Skovlund CW, Skjeldestad FE, Løkkegaard E (2011) Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001–9. BMJ 25(343):d6423CrossRefGoogle Scholar
  25. Løkkegaard ECL, Mørch LS (2018) Tibolone and risk of gynecological hormone sensitive cancer. Int J Cancer 142:2435–2440CrossRefGoogle Scholar
  26. Long CY, Liu CM, Hsu SC, Wu CH, Wang CL, Tsai EM (2006) A randomized comparative study of the effects of oral and topical estrogen therapy on the vaginal vascularization and sexual function in hysterectomized postmenopausal women. Menopause 13:737–743CrossRefGoogle Scholar
  27. Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, Anderson G, Howard BV, Thomson CA, LaCroix AZ, Wactawski-Wende J, Jackson RD, Limacher M, Margolis KL, Wassertheil-Smoller S, Beresford SA, Cauley JA, Eaton CB, Gass M, Hsia J, Johnson KC, Kooperberg C, Kuller LH, Lewis CE, Liu S, Martin LW, Ockene JK, O’Sullivan MJ, Powell LH, Simon MS, Van Horn L, Vitolins MZ, Wallace RB (2013) Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 310:1353–1368CrossRefGoogle Scholar
  28. McFadyen IJ, Forrest APM, Raab GM, Macintyre CCA (1989) Progesterone cream for cyclic breast pain. Brit Med J 289:931CrossRefGoogle Scholar
  29. Million Women Study Collaborators (2003) Breast cancer and hormone-replacement in the Million Women Study. Lancet 362:419–427CrossRefGoogle Scholar
  30. Modelska K, Cummings S (2002) Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab 87:16–23CrossRefGoogle Scholar
  31. National Institute for Health and Care Excellence (2015) Menopause: diagnosis and management. NICE guideline published 12 November 2015 (NG 23). https://www.nice.org.uk/guidance/ng23Google Scholar
  32. Nelson HD (2004) Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. JAMA 291:1610–1620CrossRefGoogle Scholar
  33. Oddsson K, Leifels-Fischer B, de Melo NR, Wiel-Masson D, Benedetto C, Verhoeven CH, Dieben TO (2005) Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial. Contraception 71:176–182CrossRefGoogle Scholar
  34. Roach RE, Helmerhorst FM, Lijfering WM, Stijnen T, Algra A, Dekkers OM (2015) Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke. Cochrane Database Syst Rev 2015 Aug 27; (8): CD011054Google Scholar
  35. Rote-Hand-Brief (2014) Kombinierte hormonale Kontrazeptiva: Unterschiede hinsichtlich des Thromboembolie-Risikos unterschiedlicher Präparate. https://www.akdae.de/Arzneimittelsicherheit/RHB/Archiv/2014/20140130.pdfGoogle Scholar
  36. Royal College of General Practitioners Oral Contraception Study (1981) Further analysis of mortality in oral contraceptive users. Lancet I:541–546Google Scholar
  37. Schubert M, Minnemann T, Hubler D, Rouskova D, Christoph A, Oettel M, Ernst M, Mellinger U, Krone W, Jockenhövel F (2004) Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab 89:5429–5434CrossRefGoogle Scholar
  38. Spitzer WO, Lewis MA, Heinemann LAJ, Thorogood M, MacRae KD (1996) Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Brit Med J 312:83–88CrossRefGoogle Scholar
  39. Stuenkel CA, Davis SR, Gompel A, Lumsden MA, Murad MH, Pinkerton JV, Santen RJ (2015) Treatment of symptoms of the menopause: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 100:3975–4011CrossRefGoogle Scholar
  40. Womens Health Initiative Steering Committee (2004) Effect of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women’s Health Initiative randomized controlled trial. JAMA 291:1701–1712CrossRefGoogle Scholar
  41. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception (1995) Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 346:1582–1588CrossRefGoogle Scholar
  42. Writing Group for the Women’s Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333CrossRefGoogle Scholar
  43. Wu C, Grandi S, Filion K, Abenhaim H, Joseph L, Eisenberg M (2013) Drospirenone-containing oral contraceptive pills and the risk of venous and arterial thrombosis: a systematic review. BJOG 120:801–811CrossRefGoogle Scholar
  44. Yang LP, Plosker GL (2012) Nomegestrol acetate/estradiol: in oral contraception. Drugs 72:1917–1928CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Gynäkologische Endokrinologie und FertilitätsstörungenUniversitäts-FrauenklinikHeidelbergDeutschland

Personalised recommendations